Drug Profile


Alternative Names: AHU-377/valsartan; Entresto; LCZ-696; LCZ-696A; Neparvis; Valsartan/AHU-377; Valsartan/sacubitril

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Antihypertensives; Biphenyl compounds; Branched-chain amino acids; Esters; Heart failure therapies; Pentanoic acids; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Heart failure
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure
  • Phase III Essential hypertension; Hypertension; Kidney disorders

Most Recent Events

  • 01 Dec 2016 Novartis Pharmaceuticals initiates the phase III OUTSTEP-HF trial for Heart failure in Germany (PO) (NCT02900378)
  • 01 Dec 2016 Novartis Pharmaceuticals initiates the phase III PARADISE-MI trial for Heart failure (in high risk patients following an acute myocardial infarction) in USA, Austria, the Netherlands and Singapore (PO) (NCT02924727, EudraCT2016-002154-20)
  • 22 Nov 2016 Efficacy data from the PARADIGM-HF phase III trial in Heart failure presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top